BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1849 related articles for article (PubMed ID: 21203900)

  • 41. Genomic large rearrangement screening of BRCA1 and BRCA2 genes in high-risk Turkish breast/ovarian cancer patients by using multiplex ligation-dependent probe amplification assay.
    Manguoğlu E; Güran S; Yamaç D; Simşek M; Akdeniz S; Colak T; Gülkesen H; Lüleci G
    Cancer Invest; 2011 Jan; 29(1):73-7. PubMed ID: 20919953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
    Joosse SA; van Beers EH; Tielen IH; Horlings H; Peterse JL; Hoogerbrugge N; Ligtenberg MJ; Wessels LF; Axwijk P; Verhoef S; Hogervorst FB; Nederlof PM
    Breast Cancer Res Treat; 2009 Aug; 116(3):479-89. PubMed ID: 18704682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
    Claes K; Machackova E; De Vos M; Mortier G; De Paepe A; Messiaen L
    Hum Mutat; 1999; 13(3):256. PubMed ID: 10090482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
    Dobricić J; Branković-Magić M; Filipović S; Radulović S
    Cancer Genet Cytogenet; 2010 Oct; 202(1):27-32. PubMed ID: 20804917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
    Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J
    Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.
    Laitman Y; Borsthein RT; Stoppa-Lyonnet D; Dagan E; Castera L; Goislard M; Gershoni-Baruch R; Goldberg H; Kaufman B; Ben-Baruch N; Zidan J; Maray T; Soussan-Gutman L; Friedman E
    Breast Cancer Res Treat; 2011 Jun; 127(2):489-95. PubMed ID: 20960228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
    Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
    Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
    Machackova E; Damborsky J; Valik D; Foretova L
    Hum Mutat; 2001 Dec; 18(6):545. PubMed ID: 11748848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.
    Armaou S; Konstantopoulou I; Anagnostopoulos T; Razis E; Boukovinas I; Xenidis N; Fountzilas G; Yannoukakos D
    Eur J Cancer; 2007 Jan; 43(2):443-53. PubMed ID: 17174087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
    Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
    Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
    Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
    Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
    Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
    Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
    Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries.
    Evans DG; Ahmed M; Bayliss S; Howard E; Lalloo F; Wallace A
    J Med Genet; 2010 Aug; 47(8):561-6. PubMed ID: 20472656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
    Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
    Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 93.